Cargando…

The prognostic utility of GRACE risk score in predictive adverse cardiovascular outcomes in patients with NSTEMI and multivessel disease

BACKGROUND: GRACE risk score models are capable of predicting all-cause mortality of non-ST elevation myocardial infarction (NSTEMI) patients. However, its utility for evaluating major adverse cardiovascular events (MACE) in NSTEMI patients with multivessel disease (MVD) remains unclear. METHODS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaokang, Wu, Hao, Li, Liangpeng, Zhao, Xiaofang, Zhang, Chao, Wang, Wei Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791745/
https://www.ncbi.nlm.nih.gov/pubmed/36572851
http://dx.doi.org/10.1186/s12872-022-03025-6
_version_ 1784859475832733696
author Chen, Xiaokang
Wu, Hao
Li, Liangpeng
Zhao, Xiaofang
Zhang, Chao
Wang, Wei Eric
author_facet Chen, Xiaokang
Wu, Hao
Li, Liangpeng
Zhao, Xiaofang
Zhang, Chao
Wang, Wei Eric
author_sort Chen, Xiaokang
collection PubMed
description BACKGROUND: GRACE risk score models are capable of predicting all-cause mortality of non-ST elevation myocardial infarction (NSTEMI) patients. However, its utility for evaluating major adverse cardiovascular events (MACE) in NSTEMI patients with multivessel disease (MVD) remains unclear. METHODS AND RESULTS: This study was designed as a retrospective cohort study that recruited patients with NSTEMI and multivessel disease between September 2013 and December 2018 in Daping Hospital, Chongqing, China. The primary outcome was a composite outcome that included all-cause mortality, recurrent angina, non-fatal myocardial infarction, coronary re-vascularization, and non-fatal strokes. Of the 827 patients with NSTEMI, 32 did not complete follow-up and 430 were excluded because of single-vessel disease. The remaining 365 NSTEMI patients with MVD had a median follow-up of 3.0 (IQR 2.6–3.3) years, 78 patients experienced outcomes. The GRACE risk score predicted the MACE (hazard ratio 1.014, 95% CI 1.006–1.021, P < 0.001). The GRACE risk score performed well in predicting all-cause mortality (c-statistic 0.72, 95% CI 0.59–0.85, P = 0.001) in MVD but was less powerful in predicting MACE (c-statistic 0.69, 95% CI 0.62–0.75, P < 0.001). When combining the GRACE risk score with the SYNTAX score, and blood urea nitrogen for predicting all-cause mortality and MACE events, the c-statistic value increased to 0.82 and 0.81 (P < 0.001). CONCLUSION: In NSTEMI patients with MVD, the GRACE score showed an acceptable predictive value for all-cause mortality, but it was less powerful in predicting MACE. Blood urea nitrogen may be valuable in assessing long-term cardiovascular events in patients with MVD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-03025-6.
format Online
Article
Text
id pubmed-9791745
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97917452022-12-27 The prognostic utility of GRACE risk score in predictive adverse cardiovascular outcomes in patients with NSTEMI and multivessel disease Chen, Xiaokang Wu, Hao Li, Liangpeng Zhao, Xiaofang Zhang, Chao Wang, Wei Eric BMC Cardiovasc Disord Research BACKGROUND: GRACE risk score models are capable of predicting all-cause mortality of non-ST elevation myocardial infarction (NSTEMI) patients. However, its utility for evaluating major adverse cardiovascular events (MACE) in NSTEMI patients with multivessel disease (MVD) remains unclear. METHODS AND RESULTS: This study was designed as a retrospective cohort study that recruited patients with NSTEMI and multivessel disease between September 2013 and December 2018 in Daping Hospital, Chongqing, China. The primary outcome was a composite outcome that included all-cause mortality, recurrent angina, non-fatal myocardial infarction, coronary re-vascularization, and non-fatal strokes. Of the 827 patients with NSTEMI, 32 did not complete follow-up and 430 were excluded because of single-vessel disease. The remaining 365 NSTEMI patients with MVD had a median follow-up of 3.0 (IQR 2.6–3.3) years, 78 patients experienced outcomes. The GRACE risk score predicted the MACE (hazard ratio 1.014, 95% CI 1.006–1.021, P < 0.001). The GRACE risk score performed well in predicting all-cause mortality (c-statistic 0.72, 95% CI 0.59–0.85, P = 0.001) in MVD but was less powerful in predicting MACE (c-statistic 0.69, 95% CI 0.62–0.75, P < 0.001). When combining the GRACE risk score with the SYNTAX score, and blood urea nitrogen for predicting all-cause mortality and MACE events, the c-statistic value increased to 0.82 and 0.81 (P < 0.001). CONCLUSION: In NSTEMI patients with MVD, the GRACE score showed an acceptable predictive value for all-cause mortality, but it was less powerful in predicting MACE. Blood urea nitrogen may be valuable in assessing long-term cardiovascular events in patients with MVD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-03025-6. BioMed Central 2022-12-26 /pmc/articles/PMC9791745/ /pubmed/36572851 http://dx.doi.org/10.1186/s12872-022-03025-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Xiaokang
Wu, Hao
Li, Liangpeng
Zhao, Xiaofang
Zhang, Chao
Wang, Wei Eric
The prognostic utility of GRACE risk score in predictive adverse cardiovascular outcomes in patients with NSTEMI and multivessel disease
title The prognostic utility of GRACE risk score in predictive adverse cardiovascular outcomes in patients with NSTEMI and multivessel disease
title_full The prognostic utility of GRACE risk score in predictive adverse cardiovascular outcomes in patients with NSTEMI and multivessel disease
title_fullStr The prognostic utility of GRACE risk score in predictive adverse cardiovascular outcomes in patients with NSTEMI and multivessel disease
title_full_unstemmed The prognostic utility of GRACE risk score in predictive adverse cardiovascular outcomes in patients with NSTEMI and multivessel disease
title_short The prognostic utility of GRACE risk score in predictive adverse cardiovascular outcomes in patients with NSTEMI and multivessel disease
title_sort prognostic utility of grace risk score in predictive adverse cardiovascular outcomes in patients with nstemi and multivessel disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791745/
https://www.ncbi.nlm.nih.gov/pubmed/36572851
http://dx.doi.org/10.1186/s12872-022-03025-6
work_keys_str_mv AT chenxiaokang theprognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT wuhao theprognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT liliangpeng theprognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT zhaoxiaofang theprognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT zhangchao theprognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT wangweieric theprognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT chenxiaokang prognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT wuhao prognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT liliangpeng prognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT zhaoxiaofang prognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT zhangchao prognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease
AT wangweieric prognosticutilityofgraceriskscoreinpredictiveadversecardiovascularoutcomesinpatientswithnstemiandmultivesseldisease